

ASX Announcement

28 July 2021



AnteoTech Signs United Kingdom Distribution Agreement for EuGeni

Highlights

- ❖ AnteoTech signs EuGeni Distribution Agreement with Apacor Limited.
- ❖ Apacor to become the exclusive EuGeni distributor in the United Kingdom (England, Wales and Scotland).
- ❖ Apacor to distribute to all markets, with joint submission for public and private tender opportunities.

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to advise that it has signed a Distribution Agreement (Agreement) with Apacor Limited (Apacor) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT)¹ in the United Kingdom.

Based in Berkshire, England, Apacor has over 25 years' experience in designing and manufacturing parasitological pre-analytical products and is a supplier of rapid testing solutions. The current Apacor team have many years' experience operating in the UK market particularly with Government tenders. The addition of the EuGeni reader and COVID-19 RDT, will diversify their product offering by adding the first high sensitivity reader-based solution to their portfolio.

AnteoTech has appointed PromedT UK as its UK Responsible Person, who will register the EuGeni reader and SARS-CoV-2 Ag RDT with the Medicines and Healthcare products Regulatory Agency (MHRA). PromedT UK on behalf of AnteoTech will take responsibility for the regulatory processes associated with the EuGeni products in Great Britain. The CE marking will continue to be recognised in Great Britain until 30 June 2023, by which point AnteoTech will apply for a UK Conformity Assessed (UKCA) mark.

Key terms of the Agreement:

- The Agreement is to commence 1 August 2021. There are no conditions precedent to the Agreement.
- The Agreement is for exclusive sales into the United Kingdom (England, Wales and Scotland).
- The initial term of the distribution agreement is for one year, extendable by an additional two years on mutual agreement.

¹ The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19

- Government or large enterprise tender opportunities: AnteoTech and Apacor will work together to assess each tender opportunity on a case-by-case basis.
- In addition to the terms outlined in this announcement, the Agreement is subject to the standard terms, conditions, and warranties typical of a contract of this type. AnteoTech has the right to terminate the Agreement with immediate effect upon the breach or non-observance of any of the terms and conditions contained in the Agreement.

AnteoTech CEO Derek Thomson said, "We are very pleased to be signing our first European distributor agreement, with Apacor for the UK. The UK has a strong history of deploying antigen rapid testing in the battle against COVID-19. To control the spread of COVID-19 the UK's NHS has procured large volumes of rapid tests and deployed them across Britain. We believe that in the future the NHS's strategy for pandemic control will include ongoing screening and testing, which the UK has already rolled out through a number of programs, such as the recently announced Daily Contact Testing Pilot Scheme.

Apacor has a strong track record and experience in securing government tenders for diagnostic products, and we look forward to working with them to introduce the high sensitivity reader based EuGeni platform as a primary tool in control of COVID-19 to the private and public sector in the UK."

Apacor CEO Anthony Bellm said, "Apacor is delighted to be partnering with AnteoTech to represent the EuGeni range in the UK.

We are excited about our future collaboration and new developments in the pipeline, especially at a time when the world needs fast and reliable testing."

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT APACOR

Apacor are based in Berkshire, England, and have over 25 years' experience in designing and manufacturing parasitological pre-analytical products and is a supplier of rapid testing solutions.

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit www.anteotech.com

